NEOPROFEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEOPROFEN (NEOPROFEN).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
| Metabolism | Ibuprofen is primarily metabolized in the liver by cytochrome P450 enzymes, mainly CYP2C9, to inactive metabolites. |
| Excretion | Ibuprofen is primarily excreted renally as metabolites (approximately 90% of the dose), with less than 1% excreted unchanged. A small fraction (≤10%) is eliminated via bile/feces. For Neoprofen (ibuprofen lysine specifically used for patent ductus arteriosus), renal excretion accounts for >90% of elimination, predominantly as glucuronide conjugates and hydroxylated metabolites. |
| Half-life | Terminal elimination half-life is approximately 2.5 to 4 hours in adults. In preterm neonates (target population for Neoprofen), half-life is prolonged due to immature renal function: mean 30.5 hours (range 20–50 hours) after first dose, decreasing to ~15 hours after third dose. Clinical relevance: requires careful dosing intervals in neonates to avoid accumulation. |
| Protein binding | Ibuprofen is highly protein bound (>99%), primarily to albumin. In neonates, lower albumin concentrations may result in slightly higher free fraction, but binding remains extensive. |
| Volume of Distribution | Volume of distribution in adults: 0.1–0.2 L/kg. In preterm neonates: higher Vd, approximately 0.2–0.4 L/kg, reflecting larger extracellular fluid volume. Clinical meaning: distributes primarily in central compartment; high Vd in neonates suggests need for loading dose. |
| Bioavailability | Neoprofen is administered intravenously, giving 100% bioavailability. Oral bioavailability of ibuprofen is >80% but not applicable for this IV formulation. |
| Onset of Action | Intravenous administration (IV): Onset of action for ductal closure typically occurs within 24–48 hours after the first dose, with full effect often requiring three doses. Analgesic/antipyretic effects from IV ibuprofen occur within 30 minutes. Oral (not applicable for Neoprofen formulation): N/A. |
| Duration of Action | Duration of ductal closure effect is sustained if closure achieved; if incomplete, further doses may be needed. Antipyretic/analgesic duration from a single IV dose is approximately 4–6 hours. In preterm neonates, hemodynamic effects (ductal constriction) persist for several hours after each infusion. |
| Molecular Weight | 206.28 |
IV: 10 mg/kg over 15 minutes, followed by 5 mg/kg at 24, 48, and 72 hours after the first dose.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 30-89 mL/min: No adjustment. CrCl <30 mL/min: Consider reducing total dose by 50%. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B or C: Avoid use; data lacking. |
| Pediatric use | Neonates (postmenstrual age >37 weeks): IV: 10 mg/kg initial dose, then 5 mg/kg at 24 and 48 hours for closure of patent ductus arteriosus. Infants >2 years: Not established. |
| Geriatric use | No specific dose adjustment; use caution due to increased risk of renal and gastrointestinal effects. |
| 1st trimester | Avoid use; NSAIDs are associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, if used in early pregnancy. |
| 2nd trimester | Use only if clearly needed; risk of oligohydramnios and premature ductus arteriosus constriction increases with long-term use. |
| 3rd trimester | Contraindicated; known risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for NEOPROFEN (NEOPROFEN).
| Placental transfer | Ibuprofen crosses the placenta; the degree is low but sufficient to cause fetal effects, particularly in the third trimester. |
| Breastfeeding | Ibuprofen is excreted into breast milk in very small amounts; however, Neoprofen (ibuprofen lysine) has limited data. Caution is advised, especially in premature infants or with high maternal doses. |
■ FDA Black Box Warning
Risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal; risk increases with duration of use and in patients with cardiovascular risk factors. Also, risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
| Serious Effects |
Hypersensitivity to ibuprofen or any componentHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsPerioperative pain in setting of coronary artery bypass graft (CABG) surgeryActive peptic ulcer disease or gastrointestinal bleedingSevere renal impairment (eGFR <30 mL/min/1.73m²)
| Precautions | May cause necrotizing enterocolitis in premature infants; monitor renal function and watch for signs of infection; avoid concurrent use of other NSAIDs; use with caution in neonates with renal impairment, bleeding disorders, or gastrointestinal issues. |
| Food/Dietary | No food interactions, as Neoprofen is administered intravenously; however, maintain enteral feedings with caution due to risk of necrotizing enterocolitis. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Neoprofen (ibuprofen) is contraindicated during pregnancy, especially during the third trimester due to the risk of premature closure of the ductus arteriosus and oligohydramnios. First trimester use may be associated with an increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester use should be avoided unless clearly necessary. |
| Fetal Monitoring | Monitor amniotic fluid volume via ultrasound if used in second or third trimester. In preterm labor setting, perform fetal echocardiography to assess ductus arteriosus patency. Assess maternal renal function and bleeding time. |
| Fertility Effects | NSAIDs like ibuprofen can impair female fertility through inhibition of prostaglandin synthesis, affecting ovulation and implantation. Reversible upon discontinuation. In males, may affect sperm motility and count. |
| Clinical Pearls | Monitor for apnea, bradycardia, and oxygen desaturation in neonates, especially those with prior history; administer over 15 minutes to reduce renal adverse effects; use with caution in patients with bleeding risk or thrombocytopenia; avoid in patients with suspected or confirmed necrotizing enterocolitis. |
| Patient Advice | This medication is used to close a patent ductus arteriosus in premature infants. · It may cause temporary kidney function changes; urine output will be monitored. · Tell the healthcare team if the infant has bleeding problems or a bleeding disorder. · The infant may need blood tests to check kidney function and platelet counts. · Notify the doctor if the infant develops breathing difficulties or unusual bruising. |